Interaction with Regulatory Agencies Worldwide to Advance the Use of Digital Health Technology in Parkinson's Disease Clinical Research: the Critical Path for Parkinson's Pre-Competitive 3DT Initiative

被引：0

作者：

Mueller, M. ^{[1
]}

Cosman, J. ^{[2
]}

Adams, J. L. ^{[3
]}

Badawy, R. ^{[4
]}

Bhatnagar, R.

Bloem, B. ^{[5
]}

Carroll, C. ^{[6
]}

Cooray, N. ^{[7
]}

Dam, T. ^{[8
]}

Dexter, D. T. ^{[9
]}

Dockendorf, M. ^{[10
]}

Dorsey, E. R.

Frasier, M. ^{[11
]}

Garcia-Gancedo, L. ^{[12
]}

Hill, D. ^{[13
]}

Kostrzebski, M.

Kunka, E. ^{[14
]}

Lindemann, M. ^{[15
]}

Mammen, J. ^{[16
]}

Meinders, M.

Mirelman, A. ^{[17
]}

Roussos, G. ^{[18
]}

Sardar, S. ^{[1
]}

Simuni, T. ^{[19
]}

Speck, R. ^{[1
]}

Stebbins, G. T. ^{[20
]}

Barowicz, K. Ward ^{[1
]}

Cedarbaum, J. M. ^{[21
]}

Stephenson, D. ^{[1
]}

机构：

[1] Crit Path Inst, Tucson, AZ USA

[2] AbbVie, Chicago, IL USA

[3] Univ Rochester, Rochester, NY USA

[4] Univ Birmingham, Birmingham, AL USA

[5] Radboud Univ Nijmegen, Nijmegen, Netherlands

[6] Univ Plymouth, Plymouth, Devon, England

[7] Univ Oxford, Oxford, England

[8] Biogen, Cambridge, MA USA

[9] Parkinsons UK, London, England

[10] Merck & Co Inc, Kenilworth, NJ USA

[11] Michael J Fox Fdn, New York, NY USA

[12] GlaxoSmithKline, Brentford, England

[13] UCL, London, England

[14] UCB Pharmaceut, Brussels, Belgium

[15] F Hoffmann Roche AG, Basel, Switzerland

[16] Univ Rhode Isl, Providence, RI USA

[17] Tel Aviv Sourasky Med Ctr, Tel Aviv, Israel

[18] Univ London, London, England

[19] Northwestern Univ, Feinberg Sch Med, Chicago, IL USA

[20] Rush Univ, Chicago, IL 60612 USA

[21] Coeruleus Clin Sci LLC, Woodbridge, NJ USA

来源：

MOVEMENT DISORDERS | 2022年 / 37卷

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

引用

页码：S21 / S22

页数：2

共 6 条

[1] A progress update on the Critical Path for Parkinson's consortium's pre-competitive 3DT initiative
Mueller, M.
Cosman, J.
Adams, J.
Badawy, R.
Bhatnagar, R.
Bloem, B.
Carroll, C.
Cooray, N.
Dam, T.
Dexter, D.
Dockendorf, M.
Dorsey, R.
Frasier, M.
Garcia-Gancedo, L.
Hill, D.
Kostrzebski, M.
Kunka, E.
Lindemann, M.
Mammen, J.
Meinders, M.
Mirelman, A.
Roussos, G.
Sardar, S.
Simuni, T.
Speck, R.
Stebbins, G.
Barowicz, K. Ward
Cedarbaum, J.
Stephenson, D.
[J]. MOVEMENT DISORDERS, 2022, 37 : S196 - S196
[2] Critical path for Parkinson's II: Global regulatory agencies support the use of dopamine transporter neuroimaging as an enrichment biomarker to enable clinical trials in early Parkinson's disease
Stephenson, D. T.
Arneric, S.
Babcock, D.
Cole, P.
Comery, T.
Gordon, M. F.
Grosset, D.
Hill, D.
Imam, S. Z.
Jarecke, C. R.
Kern, V.
Matthews, D.
Meibach, R.
Romero, K.
Roach, A.
Russell, D.
Seibyl, J.
Sherwin, P.
Sieber, B. A.
Slicker, L.
Sur, C.
Marek, K.
[J]. MOVEMENT DISORDERS, 2016, 31 : S432 - S432
[3] Optimizing Patient-Centric Clinical Outcome Assessments for Use in Parkinson's Disease Clinical Trials: Critical Path for Parkinson's Multistakeholder Initiative
Speck, R.
Trundell, D.
Cedarbaum, J. M.
Campbell, M.
Chin, P. S.
Crawford, S.
Dam, T.
Dexter, D. T.
Goldfine, A. M.
Klapper, K.
Kopil, C. M.
Lee, S. J.
Marek, K.
Matthews, H.
Mestre, T.
Morel, T.
Minchik, M.
Muller, M. L. T. M.
Schroeder, K.
Simuni, T.
Stebbins, G. T.
Yan, C. H.
Zeissler, M. L.
Stephenson, D.
[J]. MOVEMENT DISORDERS, 2022, 37 : S32 - S33
[4] Optimizing patient-centric clinical outcome assessments for use in Parkinson's disease clinical trials: Critical Path for Parkinson's multistakeholder initiative
Speck, R.
Trundell, D.
Cedarbaum, J.
Campbell, M.
Chin, P.
Crawford, S.
Dam, T.
Dexter, D.
Goldfine, A.
Klapper, K.
Kopil, C.
Lee, S.
Marek, K.
Matthews, H.
Mestre, T.
Morel, T.
Minchik, M.
Mueller, M.
Schroeder, K.
Simuni, T.
Stebbins, G.
Yan, C.
Zeissler, M. L.
Stephenson, D.
[J]. MOVEMENT DISORDERS, 2022, 37 : S355 - S355
[5] Digital Health Technology to Measure Drug Efficacy in Clinical Trials for Parkinson's Disease: A Regulatory Perspective
Sacks, Leonard
Kunkoski, Elizabeth
[J]. JOURNAL OF PARKINSONS DISEASE, 2021, 11 : S111 - S115
[6] Global regulatory agencies support the use of dopamine transporter neuroimaging for subject selection in clinical trials targeting early stage parkinson's disease - on behalf of critical path for Parkinson's (CPP) Consortium
Stephenson, D.
Cedarbaum, J.
Eberling, J.
Facheris, M.
Grosset, D.
Gordon, M.
Hill, D.
Imam, S.
Kern, V.
Klein, G.
Matthews, D.
Muglia, P.
Roach, A.
Romero, K.
Russell, D.
Seibyl, J.
Slieker, L.
Somer, E.
Sur, C.
Xie, Z.
Marek, K.
[J]. MOVEMENT DISORDERS, 2017, 32

← 1 →